Current Therapies and Emerging Drugs in the Prediabetes Pipeline Soon to Boost the Treatment Outlook
03 Jun 2021
Los Angeles, USA , June 02, 2021 (GLOBE NEWSWIRE) -- Current Therapies and Emerging Drugs in the Prediabetes Pipeline Soon to Boost the Treatment Outlook
Prominent companies such as Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, MicroBiome Therapeutics, and others are developing potential drug candidates to boost the Prediabetes treatment scenario. Out of all the emerging therapies, the late-stage product TOTUM-63 (VALBIOTIS) has shown promising results and will significantly impact the Prediabetes treatment market.
DelveInsight’s “Prediabetes Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the pipeline landscapes. It comprises Prediabetes pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Prediabetes therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prediabetes pipeline products.
Some of the key takeaways from the Prediabetes Pipeline Report
Get an overview of pipeline landscape @ Prediabetes Clinical Trials Analysis
Prediabetes is a metabolic disorder that is considered a precursor for the development of diabetes mellitus. It is characterised by higher than normal blood glucose levels that have not yet reached diabetic levels.
Prediabetes Emerging Drugs
TOTUM-63 is a unique and patented combination of 5 plant extracts designed to reduce the risk of developing T2D on prediabetic subjects. TOTUM-63 was developed to challenge perceptions of prediabetes management and help protect the health of prediabetic patients. TOTUM-63 is currently in Phase II/III clinical development program for the Prediabetes treatment.
Research and DevelopmentPhase II/IIINCT02868177: In October 2016, Valbiotis initiated a trial, “Totum-63 Effect on Glucose and Lipid Homeostasis in People With Abdominal Obesity Associated With Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia”. The primary objective of the study was to assess the beneficial effect of Totum-63 compared to a placebo on glucose homeostasis assessed by the fasting plasma glucose level in prediabetics or untreated type 2 diabetics after 24 weeks of consumption. The study got completed in April 2019.
Results:In July 2019, VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active substance: TOTUM-63), which evaluated this product’s efficacy in a prediabetic population, compared to placebo.
Eubacterium hallii is a microbiota-based dietary supplement currently under clinical intervention in subjects suffering from metabolic syndrome/prediabetes. The product is in Phase II clinical development for the treatment of Prediabetes.
Research and DevelopmentNCT04529473: In August 2020, Caelus Health initiated a trial titled “A Double-blind, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Markers of Glycaemic Control in Healthy Hyperglycaemic Males”. This study aims to evaluate the effect of administration of a next-generation probiotic, Eubacterium hallii, versus placebo on insulin sensitivity and glycemic control, in volunteers with some markers of metabolic syndrome. The trial is currently recruiting with an estimated enrollment of 100 participants and is expected to be completed in January 2022.
For further information, refer to the detailed report @ Prediabetes Pipeline Therapeutics
Scope of Prediabetes Pipeline Drug Insight
Key Questions regarding Current Prediabetes Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customised pipeline report @ Prediabetes Drugs Pipeline Report
Related Reports
DelveInsight's Prediabetes - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Prediabetes - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Prediabetes in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's "Multiple Organ Dysfunction Syndrome Market Report 2030" delivers an in-depth understanding, historical and forecasted epidemiology, market trends in the 7MM.
DelveInsight's Corneal Endothelial Dystrophy - Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
DelveInsight's Onychomycosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an overview and an understanding of historical and forecasted epidemiology.
DelveInsight's Deep Vein Thrombosis Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology in 7MM.
About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.